Halda Raises $126m For First Clinical Trial Of Its RIPTAC Modality
Heterobifunctional Molecules From A PROTAC Pioneer
Halda will take its first RIPTAC molecule into a clinical trial in prostate cancer, offering a new small molecule modality in an indication where patients and doctors prefer oral drugs.
